Progress of Nimotuzumab Application in Nasopharyngeal Carcinoma
Compared with the global average, the incidence rate of nasopharyngeal carcinoma (NPC) in China is higher, particularly in the southern regions where the mortality rate has remained persistently high. Nimotuzumab, a targeted therapy that acts on the epidermal growth factor receptor, has prompted con...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2024-11-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://www.zlfzyj.com/cn/article/doi/10.3971/j.issn.1000-8578.2024.24.0362 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850266131638517760 |
|---|---|
| author | Tianci LIANG Yue ZHAO Chenchen SONG Chaoyi ZHANG Chen CHEN Qiaoran LI Biaoxue RONG |
| author_facet | Tianci LIANG Yue ZHAO Chenchen SONG Chaoyi ZHANG Chen CHEN Qiaoran LI Biaoxue RONG |
| author_sort | Tianci LIANG |
| collection | DOAJ |
| description | Compared with the global average, the incidence rate of nasopharyngeal carcinoma (NPC) in China is higher, particularly in the southern regions where the mortality rate has remained persistently high. Nimotuzumab, a targeted therapy that acts on the epidermal growth factor receptor, has prompted continuous progress in NPC treatment. The combination of nimotuzumab with traditional radiotherapy and chemotherapy can enhance treatment efficacy, reduce adverse reactions, and improve patients’ quality of life. This article summarizes current research findings from this perspective to provide diagnostic and therapeutic strategies for NPC treatment. |
| format | Article |
| id | doaj-art-a2b5a3bfe4db40208a77a604070a06ce |
| institution | OA Journals |
| issn | 1000-8578 |
| language | zho |
| publishDate | 2024-11-01 |
| publisher | Magazine House of Cancer Research on Prevention and Treatment |
| record_format | Article |
| series | Zhongliu Fangzhi Yanjiu |
| spelling | doaj-art-a2b5a3bfe4db40208a77a604070a06ce2025-08-20T01:54:15ZzhoMagazine House of Cancer Research on Prevention and TreatmentZhongliu Fangzhi Yanjiu1000-85782024-11-01511195696110.3971/j.issn.1000-8578.2024.24.036220240362Progress of Nimotuzumab Application in Nasopharyngeal CarcinomaTianci LIANG0Yue ZHAO1Chenchen SONG2Chaoyi ZHANG3Chen CHEN4Qiaoran LI5Biaoxue RONG6Department of Oncology, The First Affiliated Hospital of Xi'an Medical University, Xi'an 710077, ChinaDepartment of Oncology, The First Affiliated Hospital of Xi'an Medical University, Xi'an 710077, ChinaDepartment of Oncology, The First Affiliated Hospital of Xi'an Medical University, Xi'an 710077, ChinaDepartment of Oncology, The First Affiliated Hospital of Xi'an Medical University, Xi'an 710077, ChinaDepartment of Oncology, The First Affiliated Hospital of Xi'an Medical University, Xi'an 710077, ChinaDepartment of Oncology, The First Affiliated Hospital of Xi'an Medical University, Xi'an 710077, ChinaDepartment of Oncology, The First Affiliated Hospital of Xi'an Medical University, Xi'an 710077, ChinaCompared with the global average, the incidence rate of nasopharyngeal carcinoma (NPC) in China is higher, particularly in the southern regions where the mortality rate has remained persistently high. Nimotuzumab, a targeted therapy that acts on the epidermal growth factor receptor, has prompted continuous progress in NPC treatment. The combination of nimotuzumab with traditional radiotherapy and chemotherapy can enhance treatment efficacy, reduce adverse reactions, and improve patients’ quality of life. This article summarizes current research findings from this perspective to provide diagnostic and therapeutic strategies for NPC treatment.http://www.zlfzyj.com/cn/article/doi/10.3971/j.issn.1000-8578.2024.24.0362nasopharyngeal carcinomanimotuzumabepidermal growth factor receptortargeted therapyantitumor treatment |
| spellingShingle | Tianci LIANG Yue ZHAO Chenchen SONG Chaoyi ZHANG Chen CHEN Qiaoran LI Biaoxue RONG Progress of Nimotuzumab Application in Nasopharyngeal Carcinoma Zhongliu Fangzhi Yanjiu nasopharyngeal carcinoma nimotuzumab epidermal growth factor receptor targeted therapy antitumor treatment |
| title | Progress of Nimotuzumab Application in Nasopharyngeal Carcinoma |
| title_full | Progress of Nimotuzumab Application in Nasopharyngeal Carcinoma |
| title_fullStr | Progress of Nimotuzumab Application in Nasopharyngeal Carcinoma |
| title_full_unstemmed | Progress of Nimotuzumab Application in Nasopharyngeal Carcinoma |
| title_short | Progress of Nimotuzumab Application in Nasopharyngeal Carcinoma |
| title_sort | progress of nimotuzumab application in nasopharyngeal carcinoma |
| topic | nasopharyngeal carcinoma nimotuzumab epidermal growth factor receptor targeted therapy antitumor treatment |
| url | http://www.zlfzyj.com/cn/article/doi/10.3971/j.issn.1000-8578.2024.24.0362 |
| work_keys_str_mv | AT tianciliang progressofnimotuzumabapplicationinnasopharyngealcarcinoma AT yuezhao progressofnimotuzumabapplicationinnasopharyngealcarcinoma AT chenchensong progressofnimotuzumabapplicationinnasopharyngealcarcinoma AT chaoyizhang progressofnimotuzumabapplicationinnasopharyngealcarcinoma AT chenchen progressofnimotuzumabapplicationinnasopharyngealcarcinoma AT qiaoranli progressofnimotuzumabapplicationinnasopharyngealcarcinoma AT biaoxuerong progressofnimotuzumabapplicationinnasopharyngealcarcinoma |